Many reports have shown a link between mismatch repair (MMR) de®ciency and loss of normal cell cycle control, particularly loss of G2 arrest. However almost all of these studies utilized transformed cell lines, and thus the involvement of other genes in this phenotype cannot be excluded. We have examined the eects of cisplatin treatment on primary embryo ®broblasts (MEFs) derived from mice in which the MMR gene Msh2 had been inactivated (Msh2
7/7
). This analysis determined that both primary Msh2 7/7 and wild type (WT) ®broblasts exhibited an essentially identical G2 arrest following cisplatin treatment. Similarly, we observed a cisplatin-induced G2 arrest in immortalized MMR de®cient (Mlh1 7/7 and Pms2
) and WT MEFs. p53 de®cient primary MEFs (p53 7/7 ) exhibited both a clear G2 arrest and an increase in cells with a DNA content of 8N in response to cisplatin. When the Msh2 and p53 defects were combined (p53 7/7 /Msh2 7/7 ) the G2 arrest was essentially identical to the p53 7/7 ®broblasts. However, the p53 7/7
/Msh2
7/7 ®broblasts demonstrated a further increase in cells with an 8N DNA content, above that seen in the p53 7/7 ®broblasts. These results suggest that loss of MMR on its own is not enough to overcome G2 arrest following exposure to cisplatin but does play a role in preventing polyploidization, or aberrant DNA reduplication, in the absence of functional p53. Oncogene (2001 Oncogene ( ) 20, 1923 Oncogene ( ± 1927 Keywords: mismatch repair; cell cycle; polyploidy; p53; DNA damage DNA mismatch repair is known to play an important role in maintaining genomic stability, due to its function in correcting DNA mismatches introduced during replication, and cells de®cient in MMR exhibit an increased mutation rate (for review see Buermeyer et al., 1999) . However the proteins that make up the MMR system have also been associated with a number of other phenotypes. Cells de®cient in MMR have been shown to be resistant to a number of clinically important drugs, such as cisplatin, temozolomide and doxorubicin (Fink et al., 1998) . This resistance may be mediated by an altered ability to engage apoptosis, as the MMR proteins have been shown to be critical in mediating the normal in vivo apoptotic response to alkylating agents (Toft et al., 1999) . Restoration of MMR activity in cell lines, either by chromosome transfer or by direct re-introduction of the gene, results in drug resensitization, demonstrating that the drug resistance is not secondary to an increase in mutation rate but is due to the direct involvement of the MMR system. In addition MMR de®ciency has also been associated with a loss of normal cell cycle controls in response to agents such as MNNG (Koi et al., 1994) , 6-thioguanine (6-TG) (Hawn et al., 1995) cisplatin (Brown et al., 1997) and ionizing radiation (IR) (Davis et al., 1998) , suggesting that the MMR system may have a regulatory role, primarily at the G2/M boundary. Indeed the activity of a number of key regulators of the cell cycle, such as p53 (Duckett et al., 1999) , p73 (Gong et al., 1999) and c-abl (Nehme et al., 1997) , are known to be modulated in a MMR dependent fashion in response to certain types of DNA damage.
Loss of MMR has also been shown to play an important role in the development of cancer. Loss of at least ®ve of the MMR proteins (MLH1, MSH2, MSH6, PMS1 and PMS2) has been shown to be associated with the hereditary cancer syndrome HNPCC (Buermeyer et al., 1999) . In addition loss of mismatch repair, and the resulting microsatellite instability phenotype, is seen in a signi®cant fraction of sporadic tumours of many dierent cancer types (Arzimanoglou et al., 1998) . It is generally assumed that loss of MMR leads to cancer due to the resulting increased mutation rate, although it has also been suggested that defective cell cycle control may be the primary oncogenic mechanism in MMR de®cient cells (Tomlinson and Bodmer, 1999) .
Nearly all studies on the role of MMR in drug resistance and cell cycle control have been performed in tumour-derived or immortalized cell lines. Such cell lines will inevitably have multiple alterations in cell cycle control, which may well interact with a de®ciency in MMR and in¯uence the apparent phenotype of MMR defects. To more clearly de®ne the role of MMR in the cell cycle response to a commonly used chemotherapeutic agent, cisplatin, we have assessed cell cycle responses in both primary and spontaneously immortalized mouse embryonic ®broblasts (MEFs) in which one of the mismatch repair proteins, Msh2, Mlh1 or Pms2, had been genetically inactivated. In addition we have also determined the response to cisplatin in p53 pro®cient and de®cient backgrounds.
MEFs were isolated from Msh2 7/7 and WT embryos taken from 13-day pregnant females. After 3 days in culture the MEFs were split into 10 cm dishes to allow cell cycle analysis using BrdU/propidium iodide staining and FACS analysis. For each embryo, separate plates were treated with 0, 5 or 10 mm cisplatin for 1 h. Cells were then harvested at 24 or 48 h post-treatment for cell cycle analysis (example histograms in Figure 1 ). As expected the WT MEFs show a clear accumulation in G2 following exposure to 5 or 10 mm cisplatin at both 24 and 48 h (Figures 1  and 2 ). The Msh2 7/7 MEFs also show a clear G2 arrest in response to cisplatin (Figures 1 and 2) . Indeed, the G2 arrest seen in the Msh2 7/7 MEFs is essentially identical to that of the WT MEFs. This suggests that in these cells an intact MMR response is not required to initiate or maintain a G2 arrest following cisplatin damage. These results are in contrast to previous studies showing loss of G2 arrest following cisplatin treatment in MMR-defective cancer cell lines (Brown et al., 1997) , and loss of G2 arrest after 6-TG or IR in MMR-defective MEFs (Davis et al., 1998) . Taken together these results suggest that in primary MEFs a MMR defect is not sucient to overcome G2 arrest in response to cisplatin, and that a MMR independent mechanism causes G2 arrest in response to cisplatin, but not 6-TG or IR. Further investigation will be required to determine the nature of the MMR-independent mechanism, however a number of other pathways leading to G2 arrest in response to DNA damage have previously been identi®ed (Dasika et al., 1999) .
Three spontaneously immortalized MEF cell lines, WT or de®cient in either Mlh1 (Mlh1
) (Prolla et al., 1998) , were also used for cell cycle analysis. As for the primary MEFs the immortalized cell lines all exhibit a clear G2 arrest in response to treatment with 5 or 10 mm cisplatin (Figure 3) . The G2 arrest observed in the Mlh1 7/7 and Pms2 7/7 immortalized MEFs is similar to that seen in the immortalized WT MEFs, although the results suggests that there is a more rapid exit from G2 arrest in the Pms2 7/7 MEFs (Figure 3 ; 10 mm/48 h time point). Therefore, as in the primary MEFs, a functional MMR system is not essential for the G2 arrest in response to cisplatin treatment.
The FACS analysis presented above does not dierentiate between G2 cells and cells in mitosis. Therefore it is possible that the MMR de®cient cells have indeed lost G2 arrest but then subsequently arrest in mitosis through a MMR independent mechanism. To address this, the mitotic index of the three immortalized MEF cell lines was determined in untreated and cisplatin treated cells. Experiments in which the mitotic spindle is disrupted by nocodozole treatment report a peak in the mitotic index at 8 h post treatment (Notterman et al., 1998) . We therefore analysed cells at either 8 or 24 h after a 1 h exposure to 10 mm cisplatin. Cells were ®xed in methanol : acetic acid (3 : 1) and dropped onto microscope slides. Mitotic cells were identi®ed based on the presence of condensed chromatin. As can be seen from Table 1 , there is no evidence of an increase in mitotic index in any of the three cell lines (indeed mitotic indices are reduced, presumably due to the arrest induced by cisplatin in other phases of the cell cycle) showing that arrest does not occur during mitosis. Our ®ndings are therefore consistent with a G2 arrest both in the presence and absence of functional MMR.
The p53 protein is known to be a key regulator of cell cycle checkpoints and its function is frequently lost Figure 1 Eect of Msh2 and p53 status on G2 arrest and DNA ploidy. Representative FACS pro®les are shown 48 h after treatment with 0, 5 or 10 mm cisplatin, as indicated, for MEFs of each of the four genotypes. The percentage of cells with a DNA content of 8N is shown on each pro®le. Primary MEFs were derived from 13-day-old embryos and maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco) supplemented with 10% foetal calf serum. After 3 or 4 days cells were trypsinized and approximately 1610 6 cells were plated out for each dose/time point to be tested. The following day the cells were exposed to 0, 5 or 10 mm cisplatin (David Bull Laboratories) for 1 h at 378C, then washed with PBS and fresh media added. Four hours before the cells were due to be harvested the media was removed and replaced with media containing 10 mm BrdU (Sigma) and incubated at 378C for a further 4 h. The cells were then trypsinized, centrifuged and ®xed in 70% ethanol. The ®xed cells were stored at 7208C and¯ow cytometric analysis was performed as described before (Brown et al., 1993 ) using a FACScan (Becton Dickinson). Statistical analysis was performed using a two-tailed Student's t-test in human tumours (Bates and Vousden, 1996) . In addition the absence of p53 has been shown to be associated with genomic instability and increasing anneuploidy (Donehower et al., 1995) . To further investigate the eect of loss of MMR on cisplatin induced cell cycle arrest we analysed primary MEFs de®cient for both Msh2 and p53 and compared them with MEFs de®cient for p53 alone using the same analysis as described above. As can be seen from Figure 2 the p53 de®cient MEFs exhibit an even stronger G2 arrest than the WT MEFs. This is likely to be due to the loss of the p53 dependent G1/S checkpoint (El-Deiry et al., 1993; Keurbitz et al., 1992) resulting in more cells entering and then arresting in G2. As was seen in the WT background, the loss of Msh2 function in a p53 de®cient background does not result in any loss of G2 arrest (Figure 2) . A previous study of MMR de®cient, cancer-derived cell lines, which did exhibit loss of G2 arrest in response to cisplatin (Brown et al., 1997) , also detected de®ciencies in p53 function (Anthoney et al., 1996) . However, in this study we detected no loss of G2 arrest even when Msh2 was genetically inactivated in a p53 de®cient background. Thus the MMR independent pathway that results in G2 arrest in response to cisplatin in primary MEFs is also able to function in the absence of p53 activity.
p53 is also thought to play a role in a second cell cycle checkpoint at the G2/M boundary to prevent aberrant reduplication of DNA (Cross et al., 1995) . Consistent with this observation our analysis detected an increase in cells with an 8N DNA content in the p53 7/7 MEFs compared with the WT MEFs (Figures 1  and 2) , in both the cisplatin treated and untreated cells (P=0.028, 0.0028, 0.0032 for 0, 5, 10 mm treated cells at 48 h post-treatment, respectively). The Msh2
7/7
MEFs showed no increase in the 8N population compared with WT MEFs. In contrast the p53
77 MEFs showed a clear increase in cells with an 8N DNA content, over and above that seen in the MEFs de®cient in p53 alone (Figures 1 and 2 ). This increase in 8N cells was observed in untreated cells (P=0.023), as well as following treatment with either 5 (P=0.025) or 10 mm (P=0.0075) cisplatin at 48 h posttreatment. The results for the p53 7/7 MEFs are not unexpected, but the increased rate of polyploidy 
/Msh2
7/7 MEFs suggests a novel role for Msh2, and therefore possibly for MMR, in the prevention of aberrant reduplication of DNA, particularly in response to cisplatin induced DNA damage. Further investigation will be required to determine if Msh2 also plays a role in preventing aberrant reduplication of DNA in response to other DNA damaging agents, such as 6-TG and IR. There are a number of potential mechanisms by which Msh2 could function to prevent aberrant reduplication. Msh2 and its heterodimeric binding partner Msh3 are known to be required for removal of non-homologous tails during recombination (Sugawara et al., 1997) . It is therefore possible that MMR proteins could be involved in signalling from unresolved or aberrant recombination structures, to allow the resolution of such structures and the appropriate completion of mitosis. In the absence of MMR and p53 such cells may not be able to complete mitosis due to the MMR defect and may then aberrantly re-enter S phase due to the defect in p53 function. Interestingly, cisplatin treatment is known to increase mitotic recombination, as judged by an increase in sister chromatid exchange, a process regulated in part by MMR proteins (Durant et al., 1999) , and the Msh2 dependent increase in the 8N population is exaggerated following cisplatin treatment. Alternatively, Msh2 could act to induce apoptosis in polyploid cells, thus eliminating them from the population. A role for MMR proteins in signalling apoptosis in response to DNA damage is already well established (Hickman and Samson, 1999; Gong et al., 1999) .
In summary, our results highlight an interdependence between the MMR and the p53 pathways. Such an interaction is supported by a number of other studies. Lee et al. (1995) showed that p53 can recognize insertion deletion loops, forming stable complexes at these lesions where it can physically interact with Msh2. p53 has also been shown to suppress nonhomologous recombination by speci®c mismatch (Dudenhoer et al., 1998) , and MMRdependent phosphorylation of p53 has been reported after methylation damage (Duckett et al., 1999) . Finally, combined loss of Msh2 and p53 has been shown to lead to embryonic lethality of female mice on a C57BL6J background and to synergistically increased tumorigenesis in males (Cranston et al., 1997) . Previous studies obtained from tumour cell lines have implicated the MMR proteins in G2 arrest. However we show here that primary cell lines (and indeed immortalized lines derived from primary cell lines) do not show an MMR dependent G2 arrest following cisplatin treatment. These results demonstrate that MMR dependent responses are highly context dependent and that the processes controlled by the MMR proteins in normal and neoplastic cells can markedly dier. We also identify a new role for MMR proteins in controlling ploidy status, and a clear interaction in this process with p53. Taken together these results have important implications for our understanding of MMR function in normal and neoplastic cells.
